| Old Articles: <Older 54151-54160 Newer> |
|---|
 |
The Motley Fool
December 16, 2011
Travis Hoium |
"Mission: Impossible" Will Test the Power of IMAX Could this movie debut give the Company a boost?   |
The Motley Fool
December 16, 2011
Dan Caplinger |
What Happened to Paramount Gold & Silver? Let's look back at how the year went for this company. |
The Motley Fool
December 16, 2011
Neha Chamaria |
Can This Stock Be the Titan of Your Portfolio? Titan Machinery's strong numbers, growth moves, and industry advantage make it a good bet. |
The Motley Fool
December 16, 2011
David Meier |
3 Portfolio Moves to Make for 2012 Fearful investors bring opportunities for the brave. Think of Zipcar as the Netflix of automobiles. |
The Motley Fool
December 16, 2011
Dan Radovsky |
Frontier's Year of Living Dangerously A much larger Frontier Communications struggled in 2011. |
The Motley Fool
December 16, 2011
Brian Orelli |
Dendreon 2011: Supply Constrained to Missed Guidance A year in review for the biotech. |
The Motley Fool
December 16, 2011
Dan Caplinger |
How 2011 Crushed Synovus Financial Let's look back at how the year went for this company. |
The Motley Fool
December 15, 2011
Tim Beyers |
3 Reasons to Believe in the Death of "Smartphones" The category is alive and well, but the terminology needs to die. |
The Motley Fool
December 15, 2011
Brian Orelli |
BioSante Shares Crushed by Placebo Effect BioSante's LibiGel efficacy is not deemed statistically significant. |
The Motley Fool
December 15, 2011
David Williamson |
1 Massive Biotech Bloodbath Trial results and FDA panels ruled the health-care sector today. |
| <Older 54151-54160 Newer> Return to current articles. |
